A compound represented by the following formula (I) or the formula (II) disclosed in the specification is a GPR119 agonist, and is used as an agent for treating diabetes:wherein one of T1, T2, T3, and T4 is N, and each of the other three independently is CR4 or, in the alternative, each of the four independently is CR4；each of R2 and R3 is hydrogen or a C1-8 alkyl group；the double line consisting of a solid line and a broken line means a single or double bond；A is (CH2)m, a bond, or the like；B is (C(R5)H)n, a bond, or the like；one of U and V is N, and the other is CR7；W is C or CR8；each of X and Y is a C1-3 alkylene group, which optionally has a halogen atom, hydroxyl etc.；Z is C(O)OR9, C(O)R10, or the like.
